0 689

Cited 51 times in

PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer

DC Field Value Language
dc.contributor.author박성윤-
dc.contributor.author서지원-
dc.contributor.author신수진-
dc.contributor.author오영택-
dc.contributor.author정대철-
dc.contributor.author조남훈-
dc.contributor.author최영득-
dc.date.accessioned2018-07-20T07:49:00Z-
dc.date.available2018-07-20T07:49:00Z-
dc.date.issued2017-
dc.identifier.issn0361-803X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160551-
dc.description.abstractOBJECTIVE: The purpose of this study was to analyze the utility of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) in the detection of a clinically significant cancers in patients with prostate cancers with a biopsy Gleason score of 6. MATERIALS AND METHODS: A group of 182 consecutively registered patients with biopsy-proven prostate cancer with a Gleason score of 6 underwent MRI and radical prostatectomy. Clinically significant cancer was surgically defined as Gleason score of 7 or greater, tumor volume of 0.5 cm3 or greater, or tumor category T3 or greater. Clinical parameters (prostate-specific antigen level, greatest percentage of biopsy core, and percentage of positive cores) and the PI-RADSv2 ratings by three independent readers (experienced readers 1 and 2, inexperienced reader 3) were investigated. Cutoffs and the diagnostic performance of PI-RADSv2 for clinically significant cancer were analyzed. RESULTS: Clinically significant cancer was found in 87.4% (159/182) of patients. The cutoff PI-RADSv2 score for clinically significant cancer was 4 for readers 1 and 2 and 5 for reader 3. The AUCs were 0.829 and 0.853 for readers 1 and 2 (p < 0.001) and 0.602 for reader 3 (p = 0.067). For reader 1, sensitivity was 89.9% (143/159); specificity, 69.6% (16/23); positive predictive value, 95.3% (143/150); negative predictive value, 50.0% (16/32); and accuracy, 87.4% (159/182). The corresponding values for reader 2 were 81.1% (129/159), 82.6% (19/23), 97.0% (129/133), 38.8% (19/49), and 81.3% (148/182). For the experienced readers, 66.7-81.3% of patients with false-negative results had clinically significant cancers with tumor volume less than 1 cm3. CONCLUSION: PI-RADSv2 may help experienced readers identify clinically significant prostate cancers in patients with a biopsy Gleason score of 6. However, some small (< 1 cm3) clinically significant cancers can be missed when PI-RADSv2 is used.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringfield, Ill., Thomas-
dc.relation.isPartOfAMERICAN JOURNAL OF ROENTGENOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHBiopsy-
dc.subject.MESHHumans-
dc.subject.MESHMagnetic Resonance Imaging/methods*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Grading-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHProstate-Specific Antigen/blood-
dc.subject.MESHProstatectomy-
dc.subject.MESHProstatic Neoplasms/diagnostic imaging*-
dc.subject.MESHProstatic Neoplasms/pathology*-
dc.subject.MESHProstatic Neoplasms/surgery-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSensitivity and Specificity-
dc.subject.MESHTumor Burden-
dc.titlePI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Radiology-
dc.contributor.googleauthorJi Won Seo-
dc.contributor.googleauthorSu-Jin Shin-
dc.contributor.googleauthorYoung Taik Oh-
dc.contributor.googleauthorDae Chul Jung-
dc.contributor.googleauthorNam Hoon Cho-
dc.contributor.googleauthorYoung Deuk Choi-
dc.contributor.googleauthorSung Yoon Park-
dc.identifier.doi10.2214/AJR.16.16981-
dc.contributor.localIdA01509-
dc.contributor.localIdA04585-
dc.contributor.localIdA04596-
dc.contributor.localIdA02390-
dc.contributor.localIdA03592-
dc.contributor.localIdA03812-
dc.contributor.localIdA04111-
dc.relation.journalcodeJ00116-
dc.identifier.eissn1546-3141-
dc.identifier.pmid28418690-
dc.identifier.urlhttps://www.ajronline.org/doi/abs/10.2214/AJR.16.16981-
dc.subject.keywordGleason score-
dc.subject.keywordMRI-
dc.subject.keywordPI-RADS-
dc.subject.keywordclinically significant cancer-
dc.subject.keywordprostate cancer-
dc.contributor.alternativeNamePark, Sung Yoon-
dc.contributor.alternativeNameSeo, Ji Won-
dc.contributor.alternativeNameShin, Su Jin-
dc.contributor.alternativeNameOh, Young Taik-
dc.contributor.alternativeNameJung, Dae Chul-
dc.contributor.alternativeNameCho, Nam Hoon-
dc.contributor.alternativeNameChoi, Young Deuk-
dc.contributor.affiliatedAuthorPark, Sung Yoon-
dc.contributor.affiliatedAuthorSeo, Ji Won-
dc.contributor.affiliatedAuthorShin, Su Jin-
dc.contributor.affiliatedAuthorOh, Young Taik-
dc.contributor.affiliatedAuthorJung, Dae Chul-
dc.contributor.affiliatedAuthorCho, Nam Hoon-
dc.contributor.affiliatedAuthorChoi, Young Deuk-
dc.citation.volume209-
dc.citation.number1-
dc.citation.startPageW1-
dc.citation.endPageW9-
dc.identifier.bibliographicCitationAMERICAN JOURNAL OF ROENTGENOLOGY, Vol.209(1) : W1-W9, 2017-
dc.identifier.rimsid44786-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.